Possible involvement of neutrophils in a serum level increase of hepatocyte growth factor in non-Hodgkin's lymphoma

2005 ◽  
Author(s):  
Takanori Toyama ◽  
Akio Ido ◽  
Hidenori Sasak ◽  
Kohichi Maeda ◽  
Kiyoshi Yamashita ◽  
...  
Keyword(s):  
Growth Factor ◽  
Serum Level ◽  
Hepatocyte Growth Factor ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Level Increase ◽  
Non Hodgkin's Lymphoma ◽  
Hepatocyte Growth

A High Pretreatment Serum Basic Fibroblast Growth Factor Concentration Is an Independent Predictor of Poor Prognosis in Non-Hodgkin’s Lymphoma

Blood ◽  
1999 ◽  
Vol 94 (10) ◽  
pp. 3334-3339 ◽  
Author(s):  
Petri Salven ◽  
Lasse Teerenhovi ◽  
Heikki Joensuu
Keyword(s):  
Survival Rate ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Basic Fibroblast Growth Factor ◽  
Hodgkin’S Lymphoma ◽  
Multivariate Analyses ◽  
Hodgkin's Lymphoma ◽  
Fibroblast Growth ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

Basic fibroblast growth factor (bFGF) is a secreted multifunctional cytokine and a potent stimulator of angiogenesis in vivo. Elevated bFGF concentrations have been detected in the serum and urine of cancer patients. We measured bFGF by enzyme-linked immunosorbent assay from sera taken from 160 non-Hodgkin’s lymphoma (NHL) patients before treatment and stored at −20°C. The patients had been observed for at least 5 years or until death. Serum bFGF concentrations (S-bFGF) ranged from undetectable to 34.7 pg/mL (median, 3.3 pg/mL). S-bFGF was detectable with a similar frequency in all subtypes of NHL. A high pretreatment S-bFGF was associated with poor overall survival. The 5-year survival rate of the patients within the highest quartile of S-bFGF concentrations (S-bFGF = 5.5 pg/mL) was only 39%, in contrast to a 60% survival rate of the patients with lower S-bFGF (P = .019). A high S-bFGF (within the highest quartile) was associated with poor outcome also in large-cell diffuse and immunoblastic lymphomas (5-year survival rates of 28% v56%, respectively; P = .027), which was the largest histologic subgroup (n = 66) within the series. In multivariate analyses, S-bFGF was an independent prognostic factor, both when the highest quartile was used as a cut-off value (P = .0079) and when S-bFGF and the other parameters were entered into the model as continuous variables (P = .024). In the multivariate analyses, S-bFGF had a noticeably stronger prognostic value than serum lactate dehydrogenase and the number of extranodal tumor sites, both of which are currently included as components in the International Prognostic Index.

C-Reactive Protein Serum Level is a Valuable and Simple Prognostic Marker in Non Hodgkin's Lymphoma

1998 ◽  
Vol 31 (3-4) ◽  
pp. 351-357 ◽  
Author(s):  
E. Legouffe ◽  
C. Rodriguez ◽  
M. C. Picgt ◽  
B. Richard ◽  
B. Klein ◽  
...  
Keyword(s):  
Serum Level ◽  
Prognostic Marker ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Protein Serum

scholarly journals A High Pretreatment Serum Vascular Endothelial Growth Factor Concentration Is Associated With Poor Outcome in Non-Hodgkin's Lymphoma

Blood ◽  
1997 ◽  
Vol 90 (8) ◽  
pp. 3167-3172 ◽  
Author(s):  
Petri Salven ◽  
Lasse Teerenhovi ◽  
Heikki Joensuu
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Vascular Endothelial ◽  
Poor Outcome ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Endothelial Growth Factor ◽  
Vegf Level

Abstract Vascular endothelial growth factor (VEGF ) is a secreted endothelial cell-specific mitogen, which is induced by hypoxia and is angiogenic in vivo. Recently, elevated serum concentrations of VEGF (S-VEGF ) have been reported in patients with cancers of various histologies. However, the prognostic significance of S-VEGF in human cancer is unknown and the origin of S-VEGF remains unsettled. We measured S-VEGF by enzyme-linked immunosorbent assay from sera taken from 82 patients with non-Hodgkin's lymphoma before treatment and stored for 9 to 15 years at −20°C. All but one of the patients had been followed-up for at least 5 years or until death. S-VEGF ranged from 15 to 964 pg/mL; median, 228 pg/mL; mean, 291 pg/mL. A higher than the median S-VEGF level was associated with a poor World Health Organization performance status, a high International Prognostic Index, a high serum lactate dehydrogenase level, and a large cell histology. Patients with lower than the median S-VEGF at diagnosis had a 71% 5-year survival rate in comparison with only 49% among those with a higher than the median S-VEGF. We conclude that a high pretreatment S-VEGF level is associated with poor outcome in non-Hodgkin's lymphoma.

Sign in / Sign up

Export Citation Format

Share Document